Literature DB >> 6375615

Calcium blockers in smooth-muscle disorders. Current status.

M L Schwartz, H H Rotmensch, P H Vlasses, R K Ferguson.   

Abstract

Calcium-entry blockers have proven efficacy in a variety of cardiovascular disorders. The effects of these agents on ionic calcium fluxes and, thus, on smooth-muscle contraction suggest that several noncardiac conditions involving smooth-muscle dysfunction may be managed with calcium antagonists. Beneficial therapeutic results have been reported in various forms of hypertension and Raynaud's phenomenon. The results of preliminary studies in treating pulmonary hypertension, cerebral arterial spasm, migraine headache, esophageal motility disorders, and myometrial hypercontractile states are encouraging. Carefully designed, large-scale and long-term clinical trials are needed to establish the therapeutic value of calcium-entry blockers in these disorders.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6375615

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  4 in total

1.  Internal medicine: calcium channel blockers.

Authors:  R V Jutzy
Journal:  West J Med       Date:  1985-07

Review 2.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

3.  Relative activities of three calcium channel antagonists on histamine, acetylcholine and antigen-induced contractions of guinea pig ileum.

Authors:  A J Ingenito
Journal:  Agents Actions       Date:  1985-12

4.  Medical treatment of esophageal achalasia. Double-blind crossover study with oral nifedipine, verapamil, and placebo.

Authors:  G Triadafilopoulos; M Aaronson; S Sackel; R Burakoff
Journal:  Dig Dis Sci       Date:  1991-03       Impact factor: 3.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.